IP Library Granted Patent US 10,106,590
Granted Patent B2
US 10,106,590 · App. 14/777,391 · Granted Oct 23, 2018

BH4 stabilized peptides and uses thereof

Inventors: Loren D. Walensky (Newton Centre, MA); Michelle L. Stewart (Brookline, MA); Lauren Barclay (Brookline, MA)
Assignee: Dana-Farber Cancer Institute, Inc.
C07K14/4747A61K9/0019A61K9/08A61K38/1761A61K45/06A61K49/0008G01N33/68A61K38/00G01N2333/47G01N2500/04G01N2500/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,106,590
App. No.
14/777,391
Granted
Oct 23, 2018
Kind
B2
Abstract

Provided herein are polypeptides containing stabilized BH4 domains of BCL-2 family proteins that are capable of binding and/or inactivating and/or modulating BAX protein, and/or its close homologs BAK and BOK, and/or other physiological BH4 targets. Also provided are compositions containing these polypeptides and methods of treating cytotoxic diseases that include administering to a subject one of the polypeptides.

Claims (10)

1. An internally cross-linked polypeptide comprising the amino acid sequence of EIVMKYIHYKLSQRGYEWDA (SEQ ID NO: 1),

wherein:

the side chains of amino acid residues at positions 8 and 12 of SEQ ID NO: 1 or the side chains of amino acid residues at positions 13 and 17 of SEQ ID NO: 1 are replaced by an internal staple; and

the internally cross-linked polypeptide is capable of specifically binding to a BAX protein; and

optionally, the amino acid residue at position 4 of SEQ ID NO: 1 is substituted with another amino acid.

2. The cross-linked polypeptide of claim 1 , wherein the side chains of amino acid residues 13 and 17 of SEQ ID NO: 1 are replaced by an internal staple.

3. A pharmaceutical composition comprising one or more of the cross-linked polypeptides of claim 1 .

4. A kit for identifying agents that interact with and/or modulate the activity of BAX protein comprising one or more of the cross-linked polypeptides of claim 1 and a polypeptide comprising the amino acid sequence of a BAX polypeptide.

5. A compound comprising one or more of the cross-linked polypeptides of claim 1 .

6. The cross-linked polypeptide of claim 1 , wherein the side chains of the amino acid residues at positions 8 and 12 of SEQ ID NO: 1 are replaced by an internal staple.

Assignments (3)
CONFIRMATORY LICENSE Recorded Nov 14, 2016
From: DANA-FARBER CANCER INST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040609/0588 →
CONFIRMATORY LICENSE Recorded Jul 1, 2016
From: DANA-FARBER CANCER INST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039237/0187 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2015
From: WALENSKY, LOREN; STEWART, MICHELLE L.; BARCLAY, LAUREN
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 037309/0618 →
Continuity (2)
Provisional Application 61792188 · Mar 15, 2013
Related Publication 20160031959A1 · Feb 4, 2016
Cited By (3)
US 12,398,178 US 12,441,775 US 12,528,846